Accelmed Announces the Acquisition of Bioventus' Advanced Rehabilitation Business

Accelmed portfolio company Click Therapeutics, Inc., (“Click”) a leader in prescription medical treatments as both prescription digital therapeutics and software-enhanced drug™ therapies, has obtained FDA marketing authorization for the first prescription digital therapeutic for the preventive treatment of episodic migraine

Keystone Dental Holdings, Inc. announced the appointment of Tony Susino as Chief Executive Officer and member of its Board of Directors, effective immediately

Dassault Systèmes announced its investment in Accelmed portfolio company Click Therapeutics, a leader in prescription digital therapeutics and software-enhanced drug therapies.

GT Medical Technologies, a medical device company with a corporate purpose of improving the lives of patients with brain tumors, announced the company has completed a $37 million first close of a Series D financing round led by Evidity Health Capital and new investor Accelmed Partners

Minerva Surgical announced the appointment of Darin Hammers as the new President and Chief Executive Officer and Member of the Board.

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced an affiliate has acquired Trukera Medical, from its private equity owner, Accelmed Partners, and other shareholders. The tuck-in acquisition will help expand Bausch + Lomb’s surgical presence in the United States and contribute to its leading position in dry eye.

Asset acquisition expands Merit’s endoscopy portfolio with a minimally invasive solution for patients suffering from chronic gastroesophageal reflux disease (GERD)

Better Therapeutics assets include the first FDA-authorized prescription digital therapeutic for type 2 diabetes, AspyreRx, as well as development candidates BT-002, BT-003 and BT-004 for hypertension, hyperlipidemia, and MASH. Initial efforts will focus on further development of AspyreRx to adapt it for the treatment of obesity and to benefit from Click’s AI-enabled platform as part of Click’s obesity digital therapeutic in development, CT-181; Click does not plan to self-commercialize AspyreRx as-is at this time. CT-181 will be optimized for combination use with anti-obesity and diabetes medications such as GLP-1s, including current injectables and future oral formulations, with the goal of improving treatment persistence, outcomes, and value.

In a landmark clinical study, this innovative adjunctive treatment delivered via smartphone app reduced depression symptoms in participants on antidepressant medication with no treatment-related adverse events

Preliminary unaudited revenue expected to be between $17.5 million and $18.0 million for Q4 2023 and between $64.9 million and $65.4 million for full year 2023, beginning 2024 with cash balance of $66.5 million. Announced completion of patient implant milestone in the NAUTILUS trial. Completed initial milestones in first strategic data collaboration, using proprietary biomarker monitoring and data analysis capabilities to support a clinical-stage biotechnology company’s clinical trial. Pilot Launch of Project CARE program to advance RNS System access to community setting expected in 1H 2024.

NAUTILUS is the first and only pivotal clinical study to evaluate neuromodulation therapy for treating drug refractory idiopathic generalized epilepsy. Neuromodulation therapy is not currently indicated for patients with drug refractory generalized epilepsy. If successful, NeuroPace’s RNS System would represent the first neuromodulation indication in idiopathic generalized epilepsy

First of its kind, multi-year collaboration leverages RNS System’s data to track responses of implanted RNS System patients enrolled in a biotechnology company’s clinical trial. In strategic data collaboration, clinical-stage biotechnology company to pay NeuroPace up to $3.7 million over two years to gain non-exclusive access to NeuroPace’s proprietary biomarker monitoring and data analysis capabilities for trial patients

Q3 revenue increased 18.9% year-over-year to $16.8M, including $11.9M from the U.S.

Check-Cap shareholders to vote on proposed Business Combination Agreement with Keystone Dental at Annual General Meeting on Monday, December 18^th, 2023

CartiHeal, founded in 2009 by Altschuler in collaboration with Ben-Gurion University, raised $74 million from venture capital funds aMoon, Elron, Peregrine Ventures, Access Medical Ventures, Pertec, Accelmed, and JJDC - the venture capital fund of J&J.

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces that it has entered into a definitive agreement to acquire CartiHeal, developer of Agili-C, a novel sports medicine technology for cartilage regeneration in the knee. Under the terms of the agreement, Smith+Nephew will pay an initial cash consideration of $180 million at closing, and up to a further $150 million contingent on financial performance.

Keystone Dental Holdings (“Keystone Dental” or the “Company”), a pioneer in dental implant technology, announced today the commercial launch of GENESIS ACTIVE^™ Implant System, a state-of-the-art surgical solution that is expected to transform how dental professionals approach implant placement and restoration.

Nexus Connect is a free software that provides real-time chairside results designed to compare intraoral scan gauge scans and give users direct feedback regarding the accuracy of their implant scans

NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced a series of key enhancements to its RNS System, all designed to streamline care. The nSight Platform, Simple Set Programming, and the Tablet Remote Monitor are all designed to simplify the experience with the RNS System for both clinicians and patients, and to improve patient care.

Proposed business combination to create a Nasdaq-listed medical device company focused on advancing the commercial execution and market development of Keystone’s comprehensive portfolio of implants, arches and other tooth replacement solutions. Keystone 2022 revenues exceeded $60 million. The combined company will trade on the NASDAQ with the ticker “KSD"Keystone 2022 revenues exceeded $60 million. The combined company will trade on the NASDAQ with the ticker “KSD"

Minerva Surgical, Inc. a women’s health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that it has entered into a share purchase agreement for the sale of 146,627,565 shares (subject to adjustment for any stock split occurring prior to closing) of its common stock in a private placement, led by Accelmed, with participation by New Enterprise Associates, at an offering price of $0.2046 per share (subject to adjustment for any stock split occurring prior to closing). Following the offering, Accelmed will become the controlling stockholder of Minerva Surgical.

Boehringer Ingelheim and Click Therapeutics today announced the launch of an expanded collaboration for the development and commercialization of a second prescription-based digital therapeutic (PDT). The companies will collaborate to develop and commercialize a novel mobile application, which combines multiple clinically validated therapeutic interventions for use alone and in combination with pharmaceutical therapy to help people with schizophrenia achieve positive clinical outcomes.

Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for CT-132. Click’s CT-132 prescription digital therapeutic is under development as an adjunctive preventive treatment for episodic migraine in patients aged 18 years and older.

Veranex, the only truly comprehensive, global, tech-enabled service provider dedicated to the MedTech industry, announced today that it has acquired Fusion Biotec (Fusion), a design and engineering leader for complex electro-mechanical diagnostic instrumentation and medical devices located in Orange, California.

— Darin Hammers appointed Chief Executive Officer
— EGS closes on $18M financing to further drive growth and adoption of the Transoral Incisionless Fundoplication (TIF) procedure

Helps Customized Rx Dermatology and Digital Health Company Accelerate Expansion of Product Offerings, Platform Technologies, and Operational Footprint to Enhance Practice Care

Veranex brings together best-in-class expertise in product design and engineering, medical device evaluation, clinical development, data management, regulatory, and market access to deliver an integrated and comprehensive solution to the MedTech market, enabling its customers to efficiently move from concept to commercialization.

The only truly comprehensive, global, tech-enabled service provider dedicated to the medical technology industry, announced today that it has acquired Medidee, a top MedTech consultancy company headquartered in Lausanne, Switzerland.

MedMinder, the leader in connected pharmacy care for polypharmacy and senior patients, announced today it has closed an additional $35 million in funding through a credit facility with SWK Holdings Corporation and additional investment from existing equity partner, Accelmed Partners.

While focusing on securing liquidity for our portfolio companies and taking measures to contain costs, we continue to seek new investments and are glad to report a new member of the Accelmed portfolio, Veranex.

Veranex — the only global, tech-enabled product development services provider focused on the medical technology industry — today announced strategic partnerships with Accelmed Partners II and Lauxera Capital Partners.

Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today announced that it has closed a $52 million upsized Series B financing

Accelmed Partners I portfolio company Keystone Dental Inc. announced the acquisition of Osteon Medical and the completion of a $25 million financing round led by Nantahala, with participation from Accelmed and Migdal Insurance.

Accelmed Ventures portfolio company CartiHeal is being acquired by Bioventus for $350 million in upfront consideration and up to $500 million including earn-outs.

Memic, a portfolio company of Accelmed, signed a definitive agreement for a SPAC merger with MedTech Acquisition Corporation (Nasdaq: MTAC) with an equity value at over $1 billion.

CartiHeal released a study validating the clear clinical benefits of its Agili-C™ implant for the treatment of cartilage lesions in arthritic and non-arthritic joints. Accelmed was the first investor in CartiHeal.

Managing Partner Dr. Uri Geiger spoke with Duane Mancini, M. Sc. for the Project Medtech podcast and discussed his background, Israel’s medical device space and what they look for in a company, among other things.

Managing Partner Dr. Uri Geiger sat down for a Q&A with Sarah Pringle of PE Hub to discuss how Accelmed distinguishes itself from traditional private equity funds, its unique differentiators and more.

Accelmed bolsters its leadership team with the addition of two industry veterans, Eric Tansky and Stephen Rubin as General Partner and Partner respectively, as well as adding Lewis Pell and Stanley Stern to its Executives Network.

Managing Partner Dr. Uri Geiger sat down with Lauren R. Rublin and Nathan-Kazis for a discussion on developments in pharma and biotech investing, innovations in healthtech, or the intersection of healthcare and technology, private equity investing in the healthcare arena, and healthtech innovations in Israel.

Accelmed Partners Leads a $40 Million Investment in MedMinder, the leading fully-integrated, end-to-end pharmacy, medication adherence and connected care solution for elderly and polypharmacy patients.

Accelmed successfully closed its oversubscribed second fund at the Fund’s hard cap of $400 million, exceeding its original $300 million target.

Accelmed Fund II, unveiled in late 2019, wrapped up this month at its hard cap, 33 percent above an original target of $300 million, founder and managing partner Uri Geiger told Buyouts. Fund II is more than 3x the size of its predecessor, closed in 2016 at $130 million.